Western Regional Blog – BC, YK, AB, NWT and Nunavut
“This particular study looked at the long-term follow-up of 428 women with advanced ovarian cancer who were treated with intraperitoneal chemotherapy in a Gynecologic Oncology Group trial.”
Maurie Markman, MD
Hello. I’m Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss a very important paper that appeared in Gynecologic Oncology.The paper was entitled “Prognostic Factors for Stage III Epithelial Ovarian Cancer Treated With Intraperitoneal Chemotherapy: A Gynecologic Oncology Group Study.”
This particular study looked at the long-term follow-up of 428 women with advanced ovarian cancer who were treated with intraperitoneal chemotherapy in a Gynecologic Oncology Group trial. To be entered into one of these trials, the largest tumor permitted after surgical cytoreduction was 1 cm. Of particular interest was the 36% of this patient population that started intraperitoneal chemotherapy with no gross residual disease. Within this population, the median progression-free survival was 43 months (almost 4 years) and the median overall survival was 110 months (more than 9 years).
I think the importance of this paper is clear. First, it demonstrates that long-term, disease-free survival and overall survival is very possible in advanced ovarian cancer in some sets of patients. Second, it indicates the importance for women with ovarian cancer to be managed by specialists who understand the appropriate management, are skilled in surgical techniques, and are willing to apply the most modern and effective therapy, which in the case of ovarian cancer includes intraperitoneal drug delivery in some patients.
I encourage you to read this interesting paper if you are involved in the management of ovarian cancer. It highlights some very important advances in the management of this malignancy. I thank you for your attention.